PTX-400 / PanTheryx - LARVOL DELTA

Effect of pentoxifylline on inflammatory markers in non-diabetic chronic kidney disease patients: A prospective, interventional, open label. (PubMed, World J Nephrol) - "In non-diabetic CKD patients, adjunctive treatment with PTX was associated with significant decreases in C-reactive protein levels and proteinuria. The reduction in proteinuria was mainly explained by changes in mean arterial pressure, followed by changes in TNF-α, indicating that hemodynamic factors may play a more prominent role than inflammatory modulation in mediating this effect."

Journal • Chronic Kidney Disease • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Oncology • Renal Disease • CRP • IL6 • TNFA

Adjunctive Pentoxifylline Enhances Clinical Remission and Reduces Inflammatory Biomarkers in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-Controlled Pilot Trial. (PubMed, Pharmaceuticals (Basel)) - " In this randomized, double-blind, placebo-controlled pilot study, 60 patients with UC were assigned to mesalamine plus placebo (Group 1) or mesalamine plus PTX 400 mg BID (Group 2) for 24 weeks. Multivariable regression confirmed that these effects were independent of demographic or disease-related confounders. Adjunctive PTX significantly enhanced clinical outcomes, reduced inflammation, and improved QoL in UC patients, supporting its potential as an effective add-on therapy to mesalamine."

Biomarker • Clinical • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • TNFA

Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study. (PubMed, Int Immunopharmacol) - P2 | "PTX may be suggested as a promising adjuvant anti-inflammatory medication for Parkinson's disease treatment."

Journal • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • AMPK • HMGB1 • mTOR

Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study. (PubMed, Inflammopharmacology) - P2 | "PTX could alleviate inflammation in patients with UC, so it might be promising adjunctive for patients with UC."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Pain • Ulcerative Colitis • IL6 • MPO • STAT3 • TCF3 • TJP1 • TNFA

Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia. (PubMed, Pathogens) - "Seventy-three patients aged 18-65 years, having multiple lesions or a single lesion ≥ 3 cm were randomized to receive: intramuscular MA (20 mg/kg/day × 20 days) plus oral PTX 400 mg thrice daily (intervention arm, n = 36) or MA plus placebo (control arm, n = 37), between 2012 and 2015. However, therapeutic failure was associated with significant overexpression of il1β and ptgs2 (p < 0.05), irrespective of study group. No clinical benefit of addition of PTX to standard treatment was detected in early mild to moderate CL caused by Leishmania (V.) panamensis."

Clinical • Journal • Dermatology • Immune Modulation • Infectious Disease • Inflammation • IL1B • PTGS2

A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients. (PubMed, Eur Rev Med Pharmacol Sci) - "Treatment with Vit. E, UDCA and PTX was both safe and effective in improving hepatic aminotransferases and inflammatory markers in Egyptian NASH patients. The superior effect of Vit. E compared to UDCA and PTX may suggest that oxidative stress plays a key role in disease progression of NASH patients. Moreover, IL6 and CCL2/MCP-1 may be used with or without ALT for treatment evaluation of NASH people."

Clinical • Journal • Hepatology • Non-alcoholic Steatohepatitis • CCL2 • IL6